BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

February 28, 2001

Study Completion Date

January 31, 2005

Conditions
Pneumonia, AspirationLung Abscess
Interventions
DRUG

Avelox (Moxifloxacin, BAY12-8039)

Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od

DRUG

Sulbactam/Ampicillin

Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid

Trial Locations (15)

13353

Berlin

14165

Berlin

14929

Treuenbrietzen

23538

Lübeck

27356

Rotenburg (Wümme)

31134

Hildesheim

33098

Paderborn

39112

Magdeburg

46045

Oberhausen

58515

Lüdenscheid

60596

Frankfurt am Main

68167

Mannheim

90419

Nuremberg

93053

Regensburg

04129

Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY